XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
The provision for income taxes consists of the following (in thousands):
Year Ended December 31,
20232022
Current:
Federal$— $— 
State(33)(24)
Total current(33)(24)
Deferred:
Federal— 137 
State— 169 
Total deferred— 306 
Income tax (expense) benefit$(33)$282 
Schedule of Effective Income Tax Rate Reconciliation
The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:
Year Ended December 31,
20232022
Federal statutory tax rate21.0 %21.0 %
State income taxes, net of federal tax benefits2.2 %4.3 %
Research and development tax credits0.1 %1.5 %
Stock compensation(3.4)%(1.4)%
Non-deductible expenses(1.4)%(0.9)%
Change in valuation allowance(18.5)%(23.9)%
Other(0.1)%— %
Effective tax rate(0.1)%0.6 %
Schedule of Deferred Tax Assets and Liabilities If the Company’s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.
December 31,
20232022
Deferred tax assets:
Net operating loss carryforwards$32,479 $29,789 
Research and development tax credits2,353 2,216 
Accruals, reserves and other1,119 349 
Interest expense2,547 2,236 
Indefinite lived assets300 362 
Stock compensation1,391 1,606 
Lease liability925 1,374 
Capitalization of research and experimentation costs2,929 2,047 
Total gross deferred tax assets44,043 39,979 
Less: valuation allowance(42,942)(38,567)
Deferred tax assets, net1,101 1,412 
Deferred tax liabilities:
Right of use assets(814)(1,206)
Basis differences in fixed and intangible assets(287)(206)
Deferred tax liabilities(1,101)(1,412)
Net deferred tax assets$— $— 
Summary of Valuation Allowance
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):
December 31,
20232022
Valuation allowance at the beginning of the year$38,567 $27,158 
Increases recorded to income tax provision4,375 11,409 
Valuation allowance at the end of the year$42,942 $38,567